-
-
-
-
-
-
-
B.Riley Starts Capricor Therapeutics (CAPR) at Buy
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
-
-
-
-
15,627 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

